Handok, Fresenius Kabi to join forces in oncology field

Handok Pharm said Friday it has signed an exclusive distribution agreement with Fresenius Kabi Korea to sell the latter’s four oncology products, including irinotecan and oxaliplatin, here in Korea.

Under the agreement, Handok plans to set up its new oncology department and introduce Fresenius Kabi’s other pipeline products.

“This alliance will pave the way for Handok to strengthen its pr...